



**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 13, 2024, Context Therapeutics Inc. (the "Company") held its Annual Meeting of Stockholders. As of April 15, 2024, the record date for the Annual Meeting, there were 15,966,053 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 8,486,458, or 53.15%, were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held and cumulative voting for directors is not permitted. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Annual Meeting.

**Proposal 1. Ratification of Appointment of Independent Registered Public Accounting Firm**

The Company's stockholders ratified the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The voting on this proposal is set forth below:

	<b>For</b>	<b>Against</b>	<b>Abstentions</b>	<b>Broker Non-Votes</b>
Ratification of CohnReznick LLP	8,364,879	117,835	3,744	---

**Proposal 2. Election of Directors**

The Company's stockholders elected the following director nominees to the Company's Board of Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified.

	<b>For</b>	<b>Withheld</b>	<b>Broker Non-Votes</b>
Richard Berman	4,774,152	1,873,694	1,838,612
Dr. Philip Kantoff	6,047,097	600,749	1,838,612
Martin Lehr	6,637,406	10,440	1,838,612
Jennifer Evans Stacey	5,028,962	1,618,884	1,838,612
Linda West	6,063,962	583,884	1,838,612

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 14, 2024

**Context Therapeutics Inc.**

By: /s/ Martin A. Lehr

Name: Martin A. Lehr

Title: Chief Executive Officer